Tieös Pharmaceuticals joins Emergence “to support next phase of growth”

Emergence client, Ontario and Moncton, New Brunswick-based Tieös Pharmaceuticals has revealed on its website that it joined the Emergence incubator “to progress its drug development initiatives and plan for its next phase of growth”. Read the Tieös statement here!

Tieös Pharmaceuticals is a next-generation biotech company focused on cancer metabolic therapies.

In its posted statement, Tieös CEO, Arun Anand, says, “As we continue to make excellent progress in our drug development, we are excited to be joining a nationally-recognized initiative such as Emergence.”

“Emergence provides us with a unique opportunity to connect with experts in our field and to accelerate many of our development plans for continued growth via access to their targeted mentorship, advisory and consulting services.”

Emergence Director, Martin Yuill explains: “We are pleased to welcome Tieös to our incubator program and are impressed by the progress they have made thus far.”

“The team at Tieös has a compelling story and we’re excited to be able to support them on their very promising journey,” says Yuill.

The Emergence Bioscience Business Incubator is a virtual business incubation program dedicated to assisting innovative start-ups and growth stage companies in the bioscience and food sectors. Emergence is designed as a multi-year program that provides clients with customized support and guidance to help bring their products and services to market.

As a virtual incubator, Emergence serves high-potential companies wherever they are located in Canada, while also providing a “soft landing” for innovative international bioscience ventures seeking to start-up or establish themselves in, or expand into, Canada.